Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).Xīn Gào, Daniel P. Petrylak, Arash Rezazadeh Kalebasty et al.|Journal of Clinical Oncology|2022Cited by 192
Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma PatientsUmamaheswar Duvvuri, Julie E. Bauman, Seungwon Kim et al.|Clinical Cancer Research|2019Cited by 42
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck CancerJulie E. Bauman, Roger B. Cohen, Ricklie Julian et al.|Cancers|2022Cited by 11
1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutationsDaniel P. Petrylak, Xīn Gào, Benjamin Garmezy et al.|Annals of Oncology|2023Cited by 10